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Cancer is a leading cause of mortality worldwide and matters are only set to worsen as
its incidence continues to rise. Traditional approaches to combat cancer include improved
prevention, early diagnosis, optimized surgery, development of novel drugs, and honing
regimens of existing anti-cancer drugs. Although discovery and development of novel and
effective anti-cancer drugs is a major research area, it is well known that oncology drug
development is a lengthy process, extremely costly and with high attrition rates. Further-
more, those drugs that do make it through the drug development mill are often quite
expensive, laden with severe side-effects and unfortunately, to date, have only demon-
strated minimal increases in overall survival. Therefore, a strong interest has emerged to
identify approved non-cancer drugs that possess anti-cancer activity, thus shortcutting the
development process. This research strategy is commonly known as drug repurposing
or drug repositioning and provides a faster path to the clinics. We have developed and
implemented a modification of the standard drug repurposing strategy that we review
here; rather than investigating target-promiscuous non-cancer drugs for possible anti-
cancer activity, we focus on the discovery of novel cancer indications for already approved
chemotherapeutic anti-cancer drugs. Clinical implementation of this strategy is normally
commenced at clinical phase II trials and includes pre-treated patients. As the response
rates to any non-standard chemotherapeutic drug will be relatively low in such a patient
cohort it is a pre-requisite that such testing is based on predictive biomarkers. This review
describes our strategy of biomarker-guided repurposing of chemotherapeutic drugs for
cancer therapy, taking the repurposing of topoisomerase I (Top1) inhibitors and Top1 as a
potential predictive biomarker as case in point.
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INTRODUCTION
Despite the significant improvements in diagnosis and treatment
experienced in the past few decades, cancer remains the leading
cause of death worldwide, and deaths from cancer are forecasted
to reach a staggering 13.2 million deaths by 2030 (1). What’s more,
these numbers are only set to worsen, as a result of population
aging and growth. Assuming that the estimated cancer-specific
and sex-specific trends continue, it is expected that the incidence
of all-cancer cases will rise from 12.7 million new cases in 2008 to
22.2 million by 2030 (2). Until now this unremitting increase has
been offset by significant improvements in prognosis, as a result of
earlier diagnosis, advances in surgical therapy, and the use of radi-
ation therapy and adjuvant systemic treatments; as a consequence
the survival rates for most cancers have increased significantly in
the past few decades. But, unless novel and dramatically improved
therapies are introduced, this compensation is unlikely to persist
(2, 3). This is particularly crucial for metastatic disease as, for
the large majority of cancers, it presents the biggest problem to
medical management, being the main cause of death of cancer
patients. In recent years our understanding of cancer biology has
improved significantly, and resulted in the development of new tar-
geted anti-cancer therapies such as targeting of the EGF-receptor
or VEGF. In spite of the initial hope that agents targeting molec-
ular alterations underlying cancer genesis and progression would
provide unparalleled therapeutic benefit, reality proved otherwise.
Overall, targeted therapies have shown relatively modest clinical
benefit, presumably due to intrinsic resistance of tumors to inhi-
bition of signaling intermediates, due mainly to redundancy in
signaling pathways in cancer cells (4–8). As a consequence, these
novel treatment modalities are not single-agent treatments as they,
most often, are combined with conventional cytotoxic drugs. In
short, many of the currently available molecular targeted cancer
drugs are very costly, provide modest improvements in overall
survival, and have significant side-effects.
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REPURPOSING OF CANCER DRUGS AS A DRUG
DEVELOPMENT STRATEGY
Although there is an acute need for developing new and better
anti-cancer drugs, the lengthy time and astronomical high costs
associated with cancer drug development, together with high fail-
ure rates and limited efficacy of targeted drugs have necessitated
alternative approaches to cancer drug discovery (9). Drug repur-
posing or repositioning is a promising approach to identify suit-
able drug candidates for treatment of cancer; essentially it entails
finding novel therapeutic indications for already approved drugs
(10–14). Departing from this drug development strategy, our labo-
ratory developed a simplified variant to identify novel therapeutic
indications for chemotherapeutic agents. Our approach differs
from the traditional view of drug repurposing in that we do not
investigate established target-promiscuous non-cancer drugs for
anti-cancer activity (10, 15, 16), but rather try to find new can-
cer indications for conventional chemotherapeutic agents. Most
types of conventional chemotherapy are considered to kill cancer
cells not by one single mechanism but by affecting several pivotal
pathways/mechanisms with the sum of cellular effects resulting in
cancer cell death. Accordingly, the efficacy of any given chemother-
apeutic agent may be difficult to foretell using a single molecular
predictor. On the other hand, some key molecules have been iden-
tified as major targets for chemotherapy drugs. With the above in
mind, one could initiate systematic analyses of gene aberrations,
mRNA expression, and/or protein determinations of known key
target molecules for given chemotherapeutic drugs, specifically
in those cancer types that are not conventionally offered these
drugs – a knowledge-driven repurposing strategy.
As the response rates to a specific chemotherapeutic drug might
be relatively low in an unselected pre-treated patient population,
it is a pre-requisite, that the repurposing strategy includes pre-
selection of those patients with a favorable molecular profile in
their cancer cells, i.e., those patients with the highest likelihood
of obtaining benefit from the treatment. One reasonable assump-
tion would be that one and the same molecule would be both a
major target for a chemotherapeutic drug and a predictive bio-
marker, a hypothesis that is supported by recent evidence. For
example, two meta-analyses recently concluded that breast can-
cer patients with amplification of the topoisomerase 2A (TOP2A)
gene have more clinical benefit from treatment with topoisomerase
II inhibitors than patients with normal TOP2A gene number in
their cancer cells (17–19). In the present review, we first describe
and discuss experiences with topoisomerase I (Top1) measure-
ments in colorectal cancer (CRC). We then turn to a discussion of
the repurposing of DNA Top1 inhibitors for treatment of breast
cancer.
REPURPOSING OF TOP1 INHIBITORS – IRINOTECAN
Several classes of cytotoxic agents, such as Top1 inhibitors
(irinotecan, topotecan), topoisomerase II inhibitors (etopo-
side),anthracyclines (epirubicin,doxorubicin,mitoxantrone), tax-
anes (docetaxel, paclitaxel), anti-mitotics (vinorelbine, eribulin),
antimetabolites (capecitabine, gemcitabine), or platinum analogs
(cisplatin, carboplatin) can be used for the treatment of cancer,
be it in the adjuvant, neoadjuvant, or metastatic setting. Each
drug class, in addition to a specific therapeutic profile, has its
own characteristic toxicity profile. The interplay of these two
parameters determines the clinical use of any given drug class,
which in many cases is disease specific. As a consequence, in cur-
rent clinical practice, various drugs are used following evidence-
based recommendations for each cancer type; for instance, drugs
such as taxanes and anthracyclines are commonly used for stan-
dard treatment of breast cancer but not CRC (20). Conversely,
camptothecins are used for standard treatment of CRC but not
breast cancer (21). These differences in standard clinical use of
chemotherapeutic agents essentially reflect the magnitude of clin-
ical benefit attained by the different drugs in clinical trials for
each specific disease. One class of anti-cancer drugs of particular
interest to us is that of Top1 inhibitors, in particular irinotecan.
Irinotecan is a derivative of camptothecin, and it has a unique
pharmacological profile, as Top1 is its only target (22), and there-
fore an obvious candidate for our knowledge-driven repurposing
strategy.
Irinotecan is a prodrug, 7-ethyl-10-[4-(1-piperidino)-1-
piperidino] carbonyloxycamptothecin (CPT-11), which is con-
verted by carboxylesterases into its active metabolite, 7-ethyl-
10-hydroxycamptothecin (SN-38), a potent Top1 inhibitor (23,
24). SN-38 functions by inhibiting the Top1 enzyme, which plays
an essential role in alleviating the topological stresses that arise
during DNA replication and transcription by nicking, relaxing,
and re-ligating the double-stranded DNA structure (22). The
current model for anti-cancer activity by irinotecan revolves
around the stabilization of (normally) transient DNA-Top1 com-
plexes (termed “cleavage complexes” or Top1cc) by SN-38, thereby
inhibiting subsequent re-ligation of the nicked DNA strand. Fol-
lowing the collision of DNA or RNA polymerases into the SN-38-
stabilized Top1cc, DNA damage occurs. It has been suggested that
upon collision with a DNA polymerase, double-strand breaks are
formed, whereas RNA polymerase collision causes the formation
of irreversible Top1cc-associated single strand breaks (22, 25, 26).
Unless repaired, this DNA damage can lead to cell death [reviewed
in (27)].
TOP1 INHIBITORS IN ROUTINE CANCER TREATMENT
Irinotecan and topotecan are the two Top1 inhibitors routinely
used in cancer treatment (Table 1). In both Europe and the United
States (US) irinotecan is recommended by national guidelines as
first or second line treatment for metastatic CRC (28, 29). Recently,
the combination of 5 FU, irinotecan, and oxaliplatin (FOLFIRI-
NOX) has been recommended in European guidelines on pancre-
atic cancer, for patients with metastatic disease, ≤75 years of age
with a good performance status (30). American guidelines, how-
ever, do not recommend the use of irinotecan for the treatment of
advanced pancreatic cancer (31). A new liposomal formulation of
irinotecan (MM-398) has recently been tested in a large phase II
study in patients with metastatic pancreatic cancer. Patient recruit-
ment has been completed, however, no results have been published
yet (32).
Topotecan is recommended for later line treatment of metasta-
tic ovarian cancer in both Europe and the US (33, 34). Also
in both Europe and the US topotecan in combination with cis-
platin is approved for the treatment of recurrent cervical cancer
(35, 36). Although European guidelines refer an overall survival
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Table 1 | Approved and recommended indications for the use of
irinotecan and topotecan.
Europe United States
IRINOTECAN
Metastatic colorectal cancer X X
Metastatic pancreatic cancer X
Metastatic small-cell lung cancer X X
TOPOTECAN
Metastatic ovarian cancer X X
Metastatic cervical cancer Xa X
Metastatic small-cell lung cancer X
aApproved by authorities but not recommended in clinical guidelines.
advantage with topotecan in combination with cisplatin compared
to monotherapy, combination therapy with topotecan is not rec-
ommended for the treatment of metastatic cervical cancer (37).
European guidelines on small-cell lung cancer (SCLC) recommend
combinations of irinotecan–cisplatin, or topotecan–cisplatin as
alternative treatment options for metastatic disease in the case
of contraindications to etoposide (a topoisomerase II inhibitor)
(38). US guidelines recommend irinotecan combined with cis-
platin (among other regimens) as first line treatment for metastatic
SCLC and irinotecan monotherapy as second line therapy (39).
A search on clinicaltrials.gov revealed that irinotecan and
topotecan alone or in combination with other drugs, currently
are being investigated for numerous other indications includ-
ing various brain tumors, sarcomas, non-small-cell lung cancer
(NSCLC), triple negative breast cancer, and gastric, esophageal,
and gastroesophageal junction cancers (32). Finally, etirinotecan
is a new polymer conjugate of irinotecan (NKTR-102). This drug
formulation has a half-life of approximately 50 days compared to
5 days for irinotecan and has shown a lower maximum concen-
tration resulting in greater systemic exposure to SN-38 compared
to irinotecan (40). It is currently investigated for the indications
SCLC, NSCLC, glioblastomas, and breast cancer (32, 41, 42).
TOPOISOMERASE I GENE STRUCTURE, EXPRESSION, AND
ACTIVITY IN CANCER
The topoisomerase I (TOP1) gene is located at 20q12, a region
that frequently undergoes copy-number alterations across can-
cer types, including melanoma, breast, colorectal, ovarian, and
gastric cancer (43–47). These copy-number alterations have been
reported to occur as either gains of chromosome 20, 20q, or as
amplification of smaller chromosomal regions, termed “ampli-
cons.”Research suggests that in CRC,TOP1 copy number increases
occur predominately in conjunction with the rest of 20q (44–
48). Amplification of the TOP1 gene is observed in a subset of
TOP1 gains, and interestingly, these two types of copy number
increases appear to have differential prognostic effects in stage
III CRC patients (49). We have recently applied a TOP1/CEN-
20 fluorescence in situ hybridization (FISH) probe mixture to
explore the TOP1 gene copy numbers in stage III CRC (44, 48).
The TOP1 and CEN-20 signals from unaffected epithelial mucosa
(n= 50) located adjacent to the tumor cells were applied to deter-
mine the diploid copy numbers in non-cancer cells. Based on
these non-cancer signals we found that 84% of the tumor sam-
ples demonstrated an increased TOP1 gene copy number and
64% had an increased TOP1/CEN-20 ratio compared with the
non-affected mucosa (44). Of the 50 stage III CRC patients, 13
(26%) had more than 4 TOP1 copies/cells and 16 (32%) had a
TOP1/CEN-20 ratio above 1.5 (44). In another study we included
154 stage III CRC chemonaïve patients and found that 55 (35.7%)
of the tumors had an increased TOP1 copy number above 4n
gene copies per cell and 44 (28.6%) had a TOP1/CEN-20 ratio
above 1.5 (48). There was no significant correlation between the
TOP1 copy number and proliferation, while multivariate analyses
demonstrated a prognostic value since theTOP1 copy number was
significantly associated with overall survival (48). In gastric can-
cer, several amplicons have been observed on 20q, including one
encompassing the TOP1 gene (43). In malignant melanoma, high
level amplifications of the TOP1 locus can be detected by FISH,
indicating the presence of an amplicon, which includesTOP1 (45).
In breast cancer, several amplicons mapped to 20q have been iden-
tified, including one covering the 20q12-q13 region (46). By FISH
analyses we have established the normal range of TOP1 copy num-
bers and found that 31% of primary breast cancer patients have
TOP1 copy number gains (≥4 copies) (50). However, it does not
appear thatTOP1 is part of the minimal common region of ampli-
fication, indicating that its amplification may occur as a passenger
to events involving of an amplicon located at 20q13.1–q13.2 (51).
A similar finding has been made in ovarian cancer (47). Taken
together, the TOP1 locus appears to undergo frequent copy num-
ber increases in several cancer types. These aberrations are either
focal in nature, i.e., amplicon-driven, or may involve larger chro-
mosomal regions, such as 20q. Numerous candidate oncogenes
located on 20q have been suggested as the targets of these copy-
number alterations. Putative targets include BCL2L1 (20q11.21),
AIB1 (20q12), and AURKA (20q13.2), which have all been impli-
cated in cancer (43, 52, 53). Whether TOP1 is truly the target of
these copy number increases, or whether these increases occur as
passenger-related events targeting alternative oncogenes, remains
to be elucidated.
Beyond the TOP1 copy-number alterations at the genomic
level, there is also frequent over-expression of TOP1 mRNA, Top1
protein or enzyme activity level in various cancer types compared
to normal adjacent non-cancerous tissue (54–56). Generally, there
appears to be a positive correlation between gene expression level,
protein level, and activity in cancer tissues (54–56).
COLORECTAL CANCER
Colorectal cancer is the most thoroughly examined cancer with
regard to Top1 expression and several studies have found increased
Top1 protein in CRC tissues compared to non-cancerous tissues.
Already in 1989, immunoblot analyses were applied to show that
Top1 protein levels were 14- to 16-fold higher in primary colon
adenocarcinoma tissue (n= 38) than in normal colonic mucosa
(57). Approximately 20–30% of the tumors presented with very
high levels of Top1 expression, whereas all normal tissue sam-
ples had low levels. Subsequent studies have largely confirmed
these data finding 2- to 40-fold increases of TOP1 mRNA, Top1
protein, or activity (55, 58) in cancer tissue. Copy-number analy-
ses showed that TOP1 was amplified in 23% of Dukes’ C CRC
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patients (n= 52) when compared to paired normal colon tissue
and these TOP1 amplified tumors had approximately two-times
higher RNA level and protein expression level than did the diploid
tumors (56). The enzyme activity of Top1 has also been evaluated
in crude nuclear extracts from CRC and normal tissue. These data
showed that the Top1 activity was significantly higher in primary
tumor tissue compared to normal tissue (n= 53) (59). In concor-
dance with Giovanella et al. (57), it was found that 20–30% of the
tumors possessed very high Top1 activity although the coefficients
of variations in these analyses were about 75–80% indicating that
these data may be somewhat ambiguous.
Studies have also compared the Top1 protein levels and activity
in metastatic CRC tissue to normal tissue and to primary CRC
tissue. These data are so far inconclusive. Apparently, the Top1
activity was significantly lower in liver metastases than in the
normal liver (n= 8) (59). The TOP1 mRNA levels in FFPE sam-
ples did not show significant changes when comparing primary
CRC tumor and liver metastasis (n= 33) (60) whereas the lev-
els of Top1 protein expression were higher in malignant cells from
tumor recurrences compared to primary tumors (n= 40) (61) and
n= 25 (62). Yet another study found concordance between Top1
protein levels in paired primary CRC and lymph node metastases
in 33 of 42 cases (63).
Other studies have investigated the protein levels of Top1 in
primary tumor CRC tissue by Immunohistochemistry (IHC).
These studies have found high Top1 expression in 45% (n= 62)
of metastatic CRC patients that received a first line 5 FU/CPT-
11 chemotherapy (64), 86% (n= 29) of primary colon cancers
(65), 31% (n= 13) among patients with recurrent CRC (66), 17%
(n= 1,313) in metastatic CRC patients (67), and a study com-
prising 498 Dukes’ stage B and C patients reported positive/high
Top1 protein expression in 48% of the cases (68). These differ-
ences may be due to differences among the studied patient cohorts,
choice of antibodies, tissue micro arrays (TMAs) versus full section
analyses and scoring systems. In brief,TOP1 mRNA, Top1 protein,
and activity are increased in CRC tissues in comparison to non-
cancerous tissues and a substantial subgroup of CRC patients has
high levels of Top1.
OTHER CANCERS
Elevated levels of Top1 have also been reported in various other
cancers. In poorly differentiated ovarian carcinomas the activity of
Top1 was found to be much higher than in non-cancerous tissue or
benign tumors (54, 69). In support of this, IHC analyses demon-
strated that Top1 protein is primarily associated with tumor cells
and much less to normal infiltrating cells (70) and increased Top1
protein expression was found in 43% of ovarian carcinomas (71).
Prostate tumors also possessed increased levels of Top1 protein lev-
els and Top1 activity compared to matched non-cancerous tissues,
whereas no difference between malignant and normal tissue was
found in kidney tumors (55). Similar over-expression of Top1 pro-
tein have been reported in urinary bladder carcinomas (77%) (72),
gastric carcinomas (68%) (73), testicular tumors (74), renal cell
carcinomas (36–100%) (75), malignant melanomas (42%) (76),
squamous cell carcinomas (92%) (77), and sarcomas (13%) (78).
In metastatic breast cancer (mBC) the Top1 protein expression
has been evaluated by IHC in FFPE tissue from 22 primary breast
cancer. It was found that 41% over-expressed Top1 (79). Inter-
estingly, the expression of Top1 protein varies from undetectable
to strongly positive among the analyzed samples, which indicate
that Top1 expression may be a suitable biomarker in a subgroup
of mBC patients.
CLINICAL STUDIES EVALUATING THE PREDICTIVE ROLE OF
TOP1
Until now the association between Top1 assessed in tumor tissue
and irinotecan efficacy has only been investigated retrospectively
and with focus on CRC. Top1 levels have been determined by IHC
where protein expression was assessed (64, 67, 68) and by RT-PCR
where gene expression (mRNA) was analyzed (60). Tumor sam-
ples were obtained from patients who were originally enrolled in
randomized phase III trials or from patients routinely treated in
accordance with current local clinical guidelines.
Two small single-cohort biomarker studies investigated patients
with advanced CRC who were all treated with different regimens
of 5 FU/leucovorin+ irinotecan (60, 64, 67, 68). These studies did
not identify any significant association betweenTOP1 gene expres-
sion or Top1 protein expression and objective response rates or
survival endpoints. However, both studies were methodologically
flawed as Top1 data was only available from 62 to 33 patients,
respectively, and due to the consequent inherent lack of sufficient
statistical power, this makes it almost impossible to obtain statis-
tically significant results even though the association in question
was in fact true. Additionally, a true distinction between a pre-
dictive and a prognostic component of a biomarker will not be
identified when survival analysis is performed in a single-cohort
study without a relevant control group (80, 81).
Biomarker studies designed to obtain Level of Evidence (LoE) 1
as proposed by Simon et al. (81) have been conducted where mate-
rial from randomized clinical phase III trials was used in order to
conduct a so-called prospective-retrospective biomarker evalua-
tion according to a stringent analysis plan. In a study by Braun et al.
(67) primary tumor material from patients originally accrued in
the UK MRC FOCUS study (82) was used. The UK MRC FOCUS
study was a randomized clinical trial investigating different combi-
nations of chemotherapy for patients with advanced CRC. In first
line 1,628 patients were randomized between 5 FU/levofolinate,
5 FU/levofolinate+ irinotecan or 5 FU/levofolinate+ oxaliplatin.
As patients in the 5 FU/levofolinate arm could be used as relevant
controls to correct for potential concurrent prognostic qualities
of the biomarkers in question, this clinical design was ideal when
investigating putative predictive biomarkers of either irinotecan or
oxaliplatin efficacy. In the biomarker study, Top1 protein expres-
sion was assessed by IHC using a murine monoclonal antibody
(clone 1D6, Novocastra), and the staining intensity was graded as
low, moderate, or high. Due to inadequate tumor material or failed
IHC analysis 315 cases were excluded, which resulted in available
Top1 data from 1,313 tumor samples (81%). The authors reported
a significant association between staining intensity and progres-
sion free survival where patients with tumors showing moderate
or high expression benefited from the addition of irinotecan com-
pared to 5 FU/levofolinate therapy alone. In contrast, patients with
Top1 low classified tumors did not benefit more from the irinote-
can combination than from the 5 FU/levofolinate treatment alone.
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The interaction between Top1 and the irinotecan combination was
reported to be statistically significant (P = 0.001). An attempt to
validate these results was performed in tumor material from the
CAIRO trial (83). In the CAIRO trial, 820 patients with advanced
CRC were originally randomized between capecitabine, a prodrug
of 5 FU, or capecitabine+ irinotecan as first line treatment. In
the following biomarker study (84), which was only published in
abstract form, tumor samples from 545 patients were included
and the same methodologies as in the study by Braun et al. (67)
were applied. The study failed to confirm the positive association
between Top1 protein expression and irinotecan efficacy. There are
several explanations to why confirmation failed. First, the hypoth-
esis may not be correct, and second, potential methodological bias
may have been introduced unintentionally. Assessment of IHC
staining intensity can be problematic and inter-observer variability
due to staining heterogeneity and the somewhat subjective nature
of the evaluation is a challenge to this methodology. Addition-
ally, information on analytical validation of the applied antibody
is essential to ensure prober sensitivity and specificity, and to our
knowledge this is lacking for the 1D6 clone, which was used in
both the CAIRO and the UK MRC FOCUS trials – as a result we
cannot objectively determine which trial, if any, may be at fault.
However, as stated previously, both the CAIRO and the UK MRC
FOCUS trials fulfill the requirements set by Simon et al. (81) in
order to obtain LoE 1 for a predictive biomarker of irinotecan
efficacy, and the trials still represent the best available option to
retrospectively assess the association between other biomarkers or
Top1 analyzed by techniques other than IHC and irinotecan in the
advanced setting of CRC.
The association between Top1 protein expression and irinote-
can efficacy has also been investigated in the adjuvant setting
of CRC, and results from a retrospective biomarker study sug-
gested a positive predictive role of Top1 protein expression (68).
The study did not use material from one randomized clini-
cal trial but included material from several clinical trials, which
resulted in two cohorts of patients who were either treated with
5 FU/leucovorin alone or 5 FU/leucovorin+ irinotecan. However,
this methodology was intrinsically flawed as the original clinical
trials spanned almost two decades, a time frame in where great
surgical improvements in the managements of CRC have taken
place.
Based on negative results from several phase III trials,
i.e., the PETACC-3 (85) and the CALGB 89803 (86), the
5 FU/leucovorin+ irinotecan combination is today not recom-
mended in the adjuvant setting of colon cancer. However, as
patients in these trials were randomized between 5 FU/leucovorin
and 5 FU/leucovorin+ irinotecan, tumor tissue from these trials is
highly appropriate for retrospective biomarker research in relation
to prediction of irinotecan efficacy. The main challenge with such
an approach is the availability of a sufficient number of tumor
samples to obtain the necessary statistical power.
DESIGN OF CLINICAL STUDIES TO VALIDATE PREDICTIVE
BIOMARKERS
Repurposing often involves drugs where the mechanisms of
action are fully or partly known. Thus, clinical repurposing tri-
als may take the advantage of such knowledge and from early
phase development/testing include predictive biomarkers. Such
biomarkers will often be found among molecules known to be
mechanistically involved in sensitivity/resistance to the drug. The
use of predictive biomarkers in early drug testing may increase the
therapeutic index of the drug in question by increasing the effi-
cacy of the drug in the selected biomarker favorable population
and at the same time avoid drug-induced toxicity in the biomarker
unfavorable population as these patients will not be exposed to the
drug. Looking ahead, future drug indications might be limited to
small subgroups of patients based on predictive biomarkers. Tar-
geted drug selection is already in routine use e.g., estrogen receptor
and human epidermal growth factor receptor (HER) 2 in breast
cancer, KRAS in CRC and BRAF in malignant melanomas. The
status of the relevant marker is frequently based only on analysis
of the primary tumor. However, in e.g., breast cancer accumu-
lating evidence suggests that tumor characteristics, including ER
and HER2 might change through tumor progression (87). Thus,
the treatment strategy may require readiness to perform serial
biopsies, including biopsies from metastatic lesions. The statistical
considerations and principles for repurposing an old drug accom-
panied by a biomarker are exactly the same as for the development
of a new (targeted) drug.
PHASE I
Most often, repurposing of an old drug will not involve a phase
I trial. However, new knowledge concerning relevant biomarkers
might encourage the clinicians to try new drug combinations and
thus perform a phase I trial.
The goal of incorporating biomarkers in this stage of develop-
ment is a better characterization of the biomarker and the assay
performance in human samples (88). In this context the present
EMA guidelines urge investigators of non-cytotoxic products to
analyze not only biopsies from the primary tumor and metastasis
but also normal tissue to understand the molecular background
for efficacy (89). More recently, molecular pre-screening has been
suggested for selecting patients for early drug development. Thus,
it is envisioned that academic institutions establish molecular
pre-screening programs in order to select patients for phase I
trials (90).
PHASE II
The biomarker should be included for hypothesis testing and early
indications for proof-of concept. There are two types of clinical
trial designs effective in evaluating the role of a potential predictive
biomarker in phase II: the adaptive parallel two stage design and
the tandem two-step predictor biomarker evaluation trial design.
The designs and rational behind them have been reviewed by
McShane et al. (88).
PHASE III
Phase III studies designed to repurpose an old drug will most often
involve late stage cancer patients in order to compare monother-
apy with a test drug versus best supportive care. Alternatively, the
test drug might be evaluated as an add-on to a known treatment.
Prospectively designed clinical trials are regarded as the gold
standard for evaluating a predictive biomarker. In many instances,
however, due to time and expenses required for these trials, a
retrospective testing of predictive biomarkers is more feasible.
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Retrospective validation of biomarkers is regarded as an accept-
able strategy in selected circumstances. The strategy requires data
from well-designed prospective phase III, randomized trials, sam-
ple availability from on a large majority of patients to avoid
bias due to patient selection, a prospectively stated hypothesis,
a predefined and standardized assay, and upfront sample size and
power justification (91). Optimally, evidence should be provided
from two independent randomized trials. KRAS as a predictor
for efficacy of cetuximab and panitumumab in CRC is an exam-
ple of a biomarker which has successfully been validated using a
retrospective strategy.
In general there are four types of clinical trial designs to evaluate
a potentially predictive biomarker: (1) the all-comers design with
a “biomarker end point” as second objective, (2) a targeted design
that restricts the study population to patients who have a favorable
predictive biomarker profile, (3) a strategy design which random-
izes patients to receive biomarker-based or non-biomarker-based
(standard) treatment, and (4) a multiple hypothesis design, which
combines the targeted design and the all-comers design. The latter
design addresses the multiple hypotheses by having co-primary
objectives (91, 92). Each of the designs has potential advantages
and disadvantages. The all-comers design requires validation in
a separate trial while the other designs prospectively evaluate the
biomarker. Choice of design should depend upon knowledge on
the biomarker and disease setting (91–94).
The REporting recommendations for tumor MARKer prog-
nostic studies (REMARK) guidelines were developed in order to
standardize and improve the quality of cancer biomarker stud-
ies. Reporting of results should follow these guidelines (95).
More recently, guidelines for conducting experiments using tissue
microarrays have been published (96). This checklist should be
used in addition to the REMARK guidelines. With a more rational
drug development including biomarker driven trials, researchers
might ultimately yield greater benefits for patients.
REPURPOSING IRINOTECAN TO BREAST CANCER
Breast cancer is the most common kind of cancer among women.
Improved adjuvant treatment in early breast cancer has resulted in
better prognosis, but still approximately 20% of women, initially
diagnosed with regional disease will develop systemic recurrence
within 5 years.
Two major, still unresolved, medical problems are that almost
all patients with mBC who obtain an objective response to
chemotherapy will eventually experience disease recurrence and
death from their disease. Secondly, a large fraction of the patients
with mBC who receive first line systemic chemotherapy will not
gain any beneficial effects from the treatment. In contrast, they
may suffer from drug-induced side-effects and in addition, initia-
tion of a potential effective second line treatment may be delayed
until lack of response to the first line treatment is evidenced.
In current treatment of mBC, the main first line cytotoxic drugs
are anthracyclines, and/or taxanes combined with cyclophos-
phamide. Second line treatment may include 5 FU, gemcitabine,
platin derivatives, or vinorelbine. Unfortunately, very few options
are available as third line treatment. It is thus clear that there is
an urgent need for new and effective drugs in this setting. On the
other hand, such drugs should be used with caution as they may
be associated with significant side-effects with severe influence on
the quality of life of the patients. If possible, such drugs should
be used in combination with predictive biomarkers, allowing for
a personalized treatment approach in which only patients with
a high likelihood of an objective response should be offered the
treatment in question. A number of publications have demon-
strated some benefit from irinotecan treatment in patients with
mBC being refractory to current breast cancer treatment (21).
However, with a relatively small group of patients obtaining bene-
fit from the treatment and the rather serious side-effects associated
with irinotecan treatment, there will be a need for a predictive
biomarker profile when introducing irinotecan in the treatment
of mBC. We describe here, using the example of repurposing of
Top1 inhibitors for the treatment of breast cancer, our approach
to identify novel therapeutic indications for standard chemother-
apeutic agents, based on prior knowledge of the pharmacology of
these agents and exploratory studies for biomarker establishment.
The gene expression level of TOP1 may not always predict
response to camptothecin (97, 98) and the currently available
antibodies to the Top1 protein have not yet been sufficiently val-
idated. FISH is a validated clinical method to be used on FFPE
tissue and it provides a direct measure of cancer cell gene aber-
rations on a cell to cell basis and may therefore provide more
specific information than global genomics techniques. Therefore,
we have used a TOP1/CEN-20 FISH probe mix to determine the
TOP1 gene aberration frequency in clinical breast cancer biop-
sies (n= 100) and compared to findings in normal breast tissue
(n= 100). These data demonstrated that TOP1 gene copy num-
bers of normal breast tissues were all in the diploid range, whereas
31% of the breast cancer samples had TOP1 copy number gain
(≥4 copies) (50). In breast cancer tissue we have observed a sig-
nificant association between the TOP1 copy numbers and the
TOP1 mRNA expression (50) which in combination with the fre-
quent amplification of the TOP1 gene suggest that TOP1 gene
copy numbers may be clinically relevant as a potential predic-
tive biomarker for irinotecan sensitivity in breast cancer. Based
on our FISH data and published reports on the response rates
of irinotecan in mBC (21), we have initiated two clinical phase
II trials with mBC patients being refractory to anthracyclines
and taxanes. Patients with TOP1 copy number gain (≥4 copies)
are offered treatment with irinotecan. The patients are stratified
according to HER2 levels being either HER2-positive (POSIRI;
EudraCT 2012-002347-23) or HER2-negative (NEGIRI; EudraCT
and 2012-002348-26). The main goal is to get objective response
rate according to RECIST 1.1. In Figure 1 we have exemplified our
approach to biomarker-guided repurposing of irinotecan in breast
cancer by picturing two individual ER-positive and HER2-neutral
breast cancer patients. These patients possess either TOP1 copy
numbers in the normal range (Figure 1A) or increasedTOP1 copy
numbers (Figure 1B) and only the latter would therefore be eligible
for irinotecan therapy. If these studies and a subsequent phase III
trial are positive, the TOP1 copy number may be applied as a pre-
dictive biomarker for irinotecan treatment in anthracycline and/or
taxane refractory mBC. Additionally, an association betweenTOP1
copy numbers and irinotecan effect should subsequently be tested
in the other cancer types not currently being treated with irinote-
can. We believe that the workflow described here can be applied to
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FIGURE 1 | Microscope photographs of two different primary breast
cancer specimens stained with a fluorescentTOP1/CEN-20
fluorescence in situ hybridization (FISH) probe mix. Red spots visualize
theTOP1 gene and green spots represent CEN-20. (A) A breast cancer
specimen with diploidTOP1 copy number of 2.97, CEN-20 copy number of
1.90, and a ratio of 1.56. (B) A breast cancer specimen with amplifiedTOP1
copy number of 6.35, CEN-20 copy number of 1.90, and a ratio of 3.34.
other chemotherapeutic drugs and/or other indications, providing
a viable shortcut to novel effective treatments.
CONCLUSION
Currently, few people would argue against that the future of drug
development in oncology lies with the identification of predictive
biomarkers capable of identifying those subsets of patients who
will benefit from a given therapy. The use of biomarkers to pin-
point those with a favorable response profile, normally a small
subgroup of patients, within a large population is at the heart of
the concept of personalized medicine. Also, the use of compan-
ion molecular diagnostics promise to minimize the size, costs, and
failure rates of cancer agents in clinical trials.
We describe here our strategy of biomarker-guided repurposing
of chemotherapeutic drugs for cancer therapy, exemplified with
the repurposing of Top1 inhibitors and Top1 as a potential predic-
tive biomarker. This approach can conceivably be implemented to
a substantial number of currently used chemotherapeutic drugs,
since their mechanisms of action are well studied with thousands
of studies available in the literature. We believe that this strategy is
valuable and can, potentially, add new tools to the armamentarium
of drugs at the disposal of oncologists.
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